 So, the key takeaway about immunotherapy from today's event is that immunotherapy is back. And it is still one of the mainstays of the treatment of kidney cancer, but I think even more importantly, we now have a new potential tool, which is the combination of stepping on the gas with interleukin-2 and taking off the break with the anti-PD-1 agents. And there are going to be clinical trials looking at that kind of a combination. And I think it's going to advance the field of immunotherapy for kidney cancer dramatically. I really anticipate that it's going to be a big deal. I still am an advocate of IL-2 because I think it's the only treatment still that can produce durable, complete responses, and that's the name of the game in kidney cancer. But even if you take the treatment and it doesn't do anything for you, you still have seven other drugs that can help you in the treatment of kidney cancer. So, immunotherapy is here to stay in the armamentarium and now we have new approaches that are going to make it even more effective. So I'm very encouraged by what we heard today. Very happy about it.